Immunomodulation

Patients with likely hemophagocytic lymphohistiocytosis or macrophage activation syndrome should begin immunomodulation while the diagnostic investigation continues, according to new EULAR/American College of Rheumatology guidelines.

Healio spoke with Ahmed Elkhanany, MD, about where future research on metastatic triple-negative breast cancer should focus.

Further research is needed to ‘deconvolute’ the risk of poor COVID-19 vaccine response in patients treated with immunomodulatory drugs, according to a presenter at the Basic and Clinical Immunology for the Busy Clinician symposium.

Adding immunomodulatory therapy to pegloticase for gout improves treatment persistence, according to data from a large observational registry presented at ACR Convergence 2021.

Combining pegloticase with immunomodulation therapy greatly improves pegloticase response rates in patients with uncontrolled gout, according to a systematic review published in Seminars in Arthritis and Rheumatism.